Evidence map›Paper›PMID 33504098›Full record

ArticleMolecules (Basel, Switzerland)2021

Dysregulation of Catalase by a Sulphamoylated Estradiol Analogue Culminates in Antimitotic Activity and Cell Death Induction in Breast Cancer Cell Lines.

Maphuti T Lebelo, Anna M Joubert, Michelle H Visagie

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Maphuti T LebeloDepartment of Physiology, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.ORCID 0000-0002-6377-8261
Anna M JoubertDepartment of Physiology, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.ORCID 0000-0002-6931-7554
Michelle H VisagieDepartment of Physiology, University of Pretoria, Private Bag X323, Gezina, Pretoria 0031, South Africa.ORCID 0000-0002-6820-7265
University of Pretoria · ZA

Funding

Cancer Association of South Africa A0V74Medical Research Council (ZA) A0W110national research foundation (ZA) 105992national research foundation (ZA) 99706National Research Foundation (ZA) 11503National Research Foundation (ZA) 90523Struwig Germeshuysen Trust A0N074The School of Medicine Research Committee of the University of Pretoria AOH561
6 · The paper itself

Abstract

Recent findings revealed that 2-ethyl-17-oxoestra-1,3,5(10)-trien-3-yl sulfamate (ESE-one) induces antiproliferative activity and cell rounding dependent on the generation of superoxide anion, hydrogen peroxide and peroxyl radical. In the current study, the role of these reactive oxygen species was assessed in the activity exerted by ESE-one on cell cycle progression, mitochondrial membrane potential and cell death induction in breast tumorigenic cells. The influence of ESE-one was also investigated on superoxide dismutase and catalase activity. ESE-one induced a time-dependent accumulation of cells in the G

Indexed as

Antimitotic AgentsAntioxidantsApoptosisAutophagyBreast NeoplasmsCatalaseCell CycleCell DeathCell Line, TumorCell ProliferationEstradiolFemaleHumansMCF-7 CellsMembrane Potential, MitochondrialReactive Oxygen SpeciesAntimitotic AgentsAntioxidantsCatalaseEstradiolReactive Oxygen SpeciesSulfonamidesSuperoxide Dismutasecatalasecell cycle progressionESE-onemitochondrial membrane depolarizationsuperoxide dismutase

Identifiers

PMID33504098
PMCPMC7866153
OpenAlexW3122173250

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.